hy-p0151 Search Results


sn50  (MedChemExpress)
95
MedChemExpress sn50
NF‐κB mediates the change in MGMT expression induced by RIP2 in glioma cells. (A) NF‐κB inhibitors SC75741 (1 μM), <t>SN50</t> (18 μM), and JSH‐23 (20 μM) inhibit MGMT protein expression in T98G/TR and U87MG/TR cells. The results were normalized to GAPDH expression and presented as the fold change in comparison with expression in the solvent control. (B) NF‐κB inhibitors SC75741, SN50, and JSH‐2 inhibit the expression of MGMT protein in T98G and U87MG cells that overexpress RIP2. The results were normalized to GAPDH expression and presented as the fold change in comparison with expression in the solvent control. Results in (A) and (B) are expressed in terms of mean ± SD from three independent experiments. ** p < 0.01, ## p < 0.01
Sn50, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hy-p0151/SN50/pmc08025621-42-2-12
Average 95 stars, based on 1 article reviews
sn50 - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier

Image Search Results


NF‐κB mediates the change in MGMT expression induced by RIP2 in glioma cells. (A) NF‐κB inhibitors SC75741 (1 μM), SN50 (18 μM), and JSH‐23 (20 μM) inhibit MGMT protein expression in T98G/TR and U87MG/TR cells. The results were normalized to GAPDH expression and presented as the fold change in comparison with expression in the solvent control. (B) NF‐κB inhibitors SC75741, SN50, and JSH‐2 inhibit the expression of MGMT protein in T98G and U87MG cells that overexpress RIP2. The results were normalized to GAPDH expression and presented as the fold change in comparison with expression in the solvent control. Results in (A) and (B) are expressed in terms of mean ± SD from three independent experiments. ** p < 0.01, ## p < 0.01

Journal: CNS Neuroscience & Therapeutics

Article Title: Regulation of temozolomide resistance in glioma cells via the RIP2/NF‐κB/MGMT pathway

doi: 10.1111/cns.13591

Figure Lengend Snippet: NF‐κB mediates the change in MGMT expression induced by RIP2 in glioma cells. (A) NF‐κB inhibitors SC75741 (1 μM), SN50 (18 μM), and JSH‐23 (20 μM) inhibit MGMT protein expression in T98G/TR and U87MG/TR cells. The results were normalized to GAPDH expression and presented as the fold change in comparison with expression in the solvent control. (B) NF‐κB inhibitors SC75741, SN50, and JSH‐2 inhibit the expression of MGMT protein in T98G and U87MG cells that overexpress RIP2. The results were normalized to GAPDH expression and presented as the fold change in comparison with expression in the solvent control. Results in (A) and (B) are expressed in terms of mean ± SD from three independent experiments. ** p < 0.01, ## p < 0.01

Article Snippet: SC75741 (HY‐10496), SN50 (HY‐P0151), JSH‐23 (HY‐13982), and lomeguatrib (HY‐13668) were obtained from MedChemExpress.

Techniques: Expressing, Comparison, Solvent, Control

Inhibition of NF‐κB or MGMT enhances the sensitivity of glioma cells to TMZ. (A) T98G/TR and U87MG/TR cells were pretreated with the NF‐κB inhibitors SC75741, SN50, and JSH‐23 and then treated with TMZ for 24 hours. Apoptosis was measured by flow cytometry. (B) T98G and U87MG cells overexpressing RIP2 were pretreated with the NF‐κB inhibitors SC75741, SN50, and JSH‐23 and then treated with TMZ for 24 hours. Apoptosis was measured by flow cytometry. (C) T98G/TR and U87MG/TR cells and RIP2‐overexpressing T98G and U87MG cells treated with lomeguatrib for 24 hours. Apoptosis was measured by flow cytometry. Results in (A), (B), and (C) are expressed in terms of mean ± SD of three independent experiments. ** p < 0.01

Journal: CNS Neuroscience & Therapeutics

Article Title: Regulation of temozolomide resistance in glioma cells via the RIP2/NF‐κB/MGMT pathway

doi: 10.1111/cns.13591

Figure Lengend Snippet: Inhibition of NF‐κB or MGMT enhances the sensitivity of glioma cells to TMZ. (A) T98G/TR and U87MG/TR cells were pretreated with the NF‐κB inhibitors SC75741, SN50, and JSH‐23 and then treated with TMZ for 24 hours. Apoptosis was measured by flow cytometry. (B) T98G and U87MG cells overexpressing RIP2 were pretreated with the NF‐κB inhibitors SC75741, SN50, and JSH‐23 and then treated with TMZ for 24 hours. Apoptosis was measured by flow cytometry. (C) T98G/TR and U87MG/TR cells and RIP2‐overexpressing T98G and U87MG cells treated with lomeguatrib for 24 hours. Apoptosis was measured by flow cytometry. Results in (A), (B), and (C) are expressed in terms of mean ± SD of three independent experiments. ** p < 0.01

Article Snippet: SC75741 (HY‐10496), SN50 (HY‐P0151), JSH‐23 (HY‐13982), and lomeguatrib (HY‐13668) were obtained from MedChemExpress.

Techniques: Inhibition, Flow Cytometry